Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma

Trial Profile

Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2019

At a glance

  • Drugs Ipilimumab (Primary) ; Paclitaxel (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jun 2019 Results (n=18) presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 08 May 2019 Planned End Date changed from 1 Apr 2019 to 1 Sep 2020.
    • 08 May 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top